RASAL2 and hepatocellular carcinoma: Additionally, PI3K/AKT signalling was found to be one of the common genomically altered pathways in mCRPC patients [2]; in particular, a previous study suggested that RASAL2 promotes cancer cell proliferation through this pathway in hepatocellular carcinoma [20].